{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:12:39Z","timestamp":1707523959500},"reference-count":56,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,7]]},"DOI":"10.7759\/cureus.46654","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T09:38:43Z","timestamp":1696844323000},"source":"Crossref","is-referenced-by-count":0,"title":["Enhancing the Oral Rehabilitation and Quality of Life of Bisphosphonate-Treated Patients: The Role of Dental Implants"],"prefix":"10.7759","author":[{"given":"Abdulaziz M","family":"Altalhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albatoul A","family":"Alsubaihi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meshaael M","family":"Aldosary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lama F","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nourah M","family":"Aldosariy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awrad K","family":"Alwegaisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal Y","family":"Alghadeer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah H","family":"Aljowayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/clr.13299","article-title":"Group 3 ITI consensus report: patient-reported outcome measures associated with implant dentistry","volume":"29","author":"Feine J","year":"2018","unstructured":"Feine J, Abou-Ayash S, Al Mardini M, et al.. Group 3 ITI consensus report: patient-reported outcome measures associated with implant dentistry. Clin Oral Implants Res. 2018, 29:270-5. 10.1111\/clr.13299","journal-title":"Clin Oral Implants Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008626026484","article-title":"Bisphosphonates in bone diseases","volume":"20","author":"Sparidans RW","year":"1998","unstructured":"Sparidans RW, Twiss IM, Talbot S. Bisphosphonates in bone diseases. Pharm World Sci. 1998, 20:206-13. 10.1023\/a:1008626026484","journal-title":"Pharm World Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs AJ","year":"2006","unstructured":"Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006, 12:6222-30s. 10.1158\/1078-0432.CCR-06-0843","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.36944","article-title":"Bisphosphonates inhibit surface-mediated osteogenesis","volume":"108","author":"Lotz EM","year":"2020","unstructured":"Lotz EM, Lohmann CH, Boyan BD, Schwartz Z. Bisphosphonates inhibit surface-mediated osteogenesis. J Biomed Mater Res A. 2020, 108:1774-86. 10.1002\/jbm.a.36944","journal-title":"J Biomed Mater Res A"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood J","year":"2002","unstructured":"Wood J, Bonjean K, Ruetz S, et al.. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002, 302:1055-61. 10.1124\/jpet.102.035295","journal-title":"J Pharmacol Exp Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2018.09.006","article-title":"Impact of bisphosphonate therapy on dental implant outcomes: an overview of systematic review evidence","volume":"48","author":"Mendes V","year":"2019","unstructured":"Mendes V, Dos Santos GO, Calasans-Maia MD, Granjeiro JM, Moraschini V. Impact of bisphosphonate therapy on dental implant outcomes: an overview of systematic review evidence. Int J Oral Maxillofac Surg. 2019, 48:373-81. 10.1016\/j.ijom.2018.09.006","journal-title":"Int J Oral Maxillofac Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla S","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, et al.. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007, 22:1479-91. 10.1359\/jbmr.0707onj","journal-title":"J Bone Miner Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2013.06.008","article-title":"Osteonecrosis of the jaw - prevention and treatment strategies for oral health professionals","volume":"49","author":"Hinchy NV","year":"2013","unstructured":"Hinchy NV, Jayaprakash V, Rossitto RA, Anders PL, Korff KC, Canallatos P, Sullivan MA. Osteonecrosis of the jaw - prevention and treatment strategies for oral health professionals. Oral Oncol. 2013, 49:878-86. 10.1016\/j.oraloncology.2013.06.008","journal-title":"Oral Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6944","article-title":"Medication-related osteonecrosis of the jaw: a review","volume":"12","author":"AlDhalaan NA","year":"2020","unstructured":"AlDhalaan NA, BaQais A, Al-Omar A. Medication-related osteonecrosis of the jaw: a review. Cureus. 2020, 12:e6944. 10.7759\/cureus.6944","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx RE","year":"2007","unstructured":"Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007, 65:2397-410. 10.1016\/j.joms.2007.08.003","journal-title":"J Oral Maxillofac Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur R","year":"2009","unstructured":"Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009, 67:1167-73. 10.1016\/j.joms.2009.02.004","journal-title":"J Oral Maxillofac Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study","volume":"41","author":"Yamazaki T","year":"2012","unstructured":"Yamazaki T, Yamori M, Ishizaki T, et al.. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg. 2012, 41:1397-403. 10.1016\/j.ijom.2012.06.020","journal-title":"Int J Oral Maxillofac Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5624\/isd.2017.47.1.45","article-title":"Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates","volume":"47","author":"Jeong HG","year":"2017","unstructured":"Jeong HG, Hwang JJ, Lee JH, Kim YH, Na JY, Han SS. Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates. Imaging Sci Dent. 2017, 47:45-50. 10.5624\/isd.2017.47.1.45","journal-title":"Imaging Sci Dent"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010239","article-title":"Management of tooth extraction in patients taking antiresorptive drugs: an evidence mapping review and meta-analysis","volume":"12","author":"Liu C","year":"2022","unstructured":"Liu C, Xiong YT, Zhu T, Liu W, Tang W, Zeng W. Management of tooth extraction in patients taking antiresorptive drugs: an evidence mapping review and meta-analysis. J Clin Med. 2022, 12:239. 10.3390\/jcm12010239","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5037\/jomr.2018.9302","article-title":"Dental implant placement in patients on bisphosphonate therapy: a systematic review","volume":"9","author":"Gelazius R","year":"2018","unstructured":"Gelazius R, Poskevicius L, Sakavicius D, Grimuta V, Juodzbalys G. Dental implant placement in patients on bisphosphonate therapy: a systematic review. J Oral Maxillofac Res. 2018, 9:e2. 10.5037\/jomr.2018.9302","journal-title":"J Oral Maxillofac Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ma16186078","article-title":"Bisphosphonates and dental implants: a systematic review and meta-analysis","volume":"16","author":"Sulaiman N","year":"2023","unstructured":"Sulaiman N, Fadhul F, Chrcanovic BR. Bisphosphonates and dental implants: a systematic review and meta-analysis. Materials. 2023, 16:6078. 10.3390\/ma16186078","journal-title":"Materials"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1563\/aaid-joi-D-19-00088","article-title":"Success rate and safety of dental implantology in patients treated with antiresorptive medication: a systematic review","volume":"47","author":"Papadakis I","year":"2021","unstructured":"Papadakis I, Spanou A, Kalyvas D. Success rate and safety of dental implantology in patients treated with antiresorptive medication: a systematic review. J Oral Implantol. 2021, 47:169-80. 10.1563\/aaid-joi-D-19-00088","journal-title":"J Oral Implantol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1563\/aaid-joi-D-19-00351","article-title":"Dental implant placement in patients with a history of medications related to osteonecrosis of the jaws: a systematic review","volume":"47","author":"Sher J","year":"2021","unstructured":"Sher J, Kirkham-Ali K, Luo JD, Miller C, Sharma D. Dental implant placement in patients with a history of medications related to osteonecrosis of the jaws: a systematic review. J Oral Implantol. 2021, 47:249-68. 10.1563\/aaid-joi-D-19-00351","journal-title":"J Oral Implantol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update","volume":"80","author":"Ruggiero SL","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg. 2022, 80:920-43. 10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30485","article-title":"The effect of antiresorptive drug holidays on medication-related osteonecrosis of the jaw: a systematic review and meta-analysis","volume":"14","author":"Aboalela AA","year":"2022","unstructured":"Aboalela AA, Farook FF, Alqahtani AS, Almousa MA, Alanazi RT, Almohammadi DS. The effect of antiresorptive drug holidays on medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. Cureus. 2022, 14:e30485. 10.7759\/cureus.30485","journal-title":"Cureus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.22691","article-title":"Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: systematic review","volume":"24","author":"Granate-Marques A","year":"2019","unstructured":"Granate-Marques A, Polis-Yanes C, Seminario-Amez M, Jan\u00e9-Salas E, L\u00f3pez-L\u00f3pez J. Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: systematic review. Med Oral Patol Oral Cir Bucal. 2019, 24:e195-203. 10.4317\/medoral.22691","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.24.18_SUPPL.18628","article-title":"Bisphosphonates and oral cavity avascular bone necrosis: a review of 12 cases","volume":"24","author":"Salesi N","year":"2006","unstructured":"Salesi N, Pistilli R, Marcelli V, et al.. Bisphosphonates and oral cavity avascular bone necrosis: a review of 12 cases. J Clin Oncol. 2006, 24:18628. 10.1200\/JCO.2006.24.18_SUPPL.18628","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2014.04.037","article-title":"Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws","volume":"72","author":"Holzinger D","year":"2014","unstructured":"Holzinger D, Seemann R, Matoni N, Ewers R, Millesi W, Wutzl A. Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2014, 72:1937.e1-8. 10.1016\/j.joms.2014.04.037","journal-title":"J Oral Maxillofac Surg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/clr.12088","article-title":"Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment","volume":"25","author":"Kwon TG","year":"2014","unstructured":"Kwon TG, Lee CO, Park JW, Choi SY, Rijal G, Shin HI. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res. 2014, 25:632-40. 10.1111\/clr.12088","journal-title":"Clin Oral Implants Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115493","article-title":"Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton","volume":"139","author":"Rogers MJ","year":"2020","unstructured":"Rogers MJ, M\u00f6nkk\u00f6nen J, Munoz MA. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020, 139:115493. 10.1016\/j.bone.2020.115493","journal-title":"Bone"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.1.131","article-title":"Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs","volume":"56","author":"Benford HL","year":"1999","unstructured":"Benford HL, Frith JC, Auriola S, M\u00f6nkk\u00f6nen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol. 1999, 56:131-40. 10.1124\/mol.56.1.131","journal-title":"Mol Pharmacol"},{"key":"ref27","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford JE","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, et al.. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001, 296:235-42.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650091206","article-title":"Structural requirements for bisphosphonate actions in vitro","volume":"9","author":"van Beek E","year":"1994","unstructured":"van Beek E, Hoekstra M, van de Ruit M, L\u00f6wik C, Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res. 1994, 9:1875-82. 10.1002\/jbmr.5650091206","journal-title":"J Bone Miner Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7498","article-title":"Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement","volume":"319","author":"Curry SJ","year":"2018","unstructured":"Curry SJ, Krist AH, Owens DK, et al.. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2018, 319:2521-31. 10.1001\/jama.2018.7498","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.6537","article-title":"Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"319","author":"Viswanathan M","year":"2018","unstructured":"Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, Kahwati LC. Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018, 319:2532-51. 10.1001\/jama.2018.6537","journal-title":"JAMA"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.115724","article-title":"The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate","volume":"69","author":"Twiss IM","year":"2001","unstructured":"Twiss IM, Burggraaf J, Schoemaker RC, van Elburg RM, den Hartigh J, Cohen AF, Vermeij P. The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. Clin Pharmacol Ther. 2001, 69:431-7. 10.1067\/mcp.2001.115724","journal-title":"Clin Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286781","article-title":"A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans","volume":"46","author":"Twiss IM","year":"2006","unstructured":"Twiss IM, van den Berk AH, de Kam ML, Bosch JJ, Cohen AF, Vermeij P, Burggraaf J. A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans. J Clin Pharmacol. 2006, 46:483-7. 10.1177\/0091270006286781","journal-title":"J Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz BJ","year":"1995","unstructured":"Gertz BJ, Holland SD, Kline WF, et al.. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995, 58:288-98. 10.1016\/0009-9236(95)90245-7","journal-title":"Clin Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin JH","year":"1996","unstructured":"Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996, 18:75-85. 10.1016\/8756-3282(95)00445-9","journal-title":"Bone"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-001-0411-8","article-title":"A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis","volume":"57","author":"Cremers S","year":"2002","unstructured":"Cremers S, Sparidans R, den HJ, Hamdy N, Vermeij P, Papapoulos S. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol. 2002, 57:883-90. 10.1007\/s00228-001-0411-8","journal-title":"Eur J Clin Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(96)00182-2","article-title":"Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones","volume":"19","author":"Masarachia P","year":"1996","unstructured":"Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone. 1996, 19:281-90. 10.1016\/8756-3282(96)00182-2","journal-title":"Bone"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(94)00035-x","article-title":"Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models","volume":"16","author":"Azuma Y","year":"1995","unstructured":"Azuma Y, Sato H, Oue Y,  Okabe K, Ohta T, Tsuchimoto M, Kiyoki M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone. 1995, 16:235-45. 10.1016\/8756-3282(94)00035-x","journal-title":"Bone"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e","article-title":"The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis","volume":"44","author":"Frith JC","year":"2001","unstructured":"Frith JC, M\u00f6nkk\u00f6nen J, Auriola S, M\u00f6nkk\u00f6nen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001, 44:2201-10. 10.1002\/1529-0131(200109)44:9&lt;2201::aid-art374&gt;3.0.co;2-e","journal-title":"Arthritis Rheum"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04304.x","article-title":"Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function","volume":"37","author":"Berenson JR","year":"1997","unstructured":"Berenson JR, Rosen L, Vescio R, et al.. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol. 1997, 37:285-90. 10.1002\/j.1552-4604.1997.tb04304.x","journal-title":"J Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007301801","article-title":"Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function","volume":"47","author":"Bergner R","year":"2007","unstructured":"Bergner R, Henrich DM, Hoffmann M, et al.. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function. J Clin Pharmacol. 2007, 47:942-50. 10.1177\/0091270007301801","journal-title":"J Clin Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-415853-5.00080-7","article-title":"Chapter 80 - bisphosphonates: pharmacology and use in the treatment of osteoporosis","author":"Diab DL","year":"2013","unstructured":"Diab DL, Watts NB, Miller PD. Chapter 80 - bisphosphonates: pharmacology and use in the treatment of osteoporosis. Osteoporosis. Marcus R, Feldman D, Dempster DW, Luckey M, Cauley JA (ed): Academic Press, Cambridge, MA; 2013. 1859-72. 10.1016\/B978-0-12-415853-5.00080-7"},{"key":"ref42","article-title":"Bisphosphonate","author":"Ganesan K","year":"2023","unstructured":"Ganesan K, Goyal A, Roane D. Bisphosphonate. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown JP","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR, et al.. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002, 71:103-11. 10.1007\/s00223-002-2011-8","journal-title":"Calcif Tissue Int"},{"key":"ref44","article-title":"Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer T","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, et al.. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000, 12:1-12.","journal-title":"Aging (Milano)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller PD","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L, et al.. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005, 20:1315-22. 10.1359\/JBMR.050313","journal-title":"J Bone Miner Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1124\/mol.61.5.1255","article-title":"Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP\/ATP translocase by a nonhydrolyzable, adenine-containing metabolite","volume":"61","author":"Lehenkari PP","year":"2002","unstructured":"Lehenkari PP, Kellinsalmi M, N\u00e4p\u00e4nkangas JP, et al.. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP\/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002, 61:1255-62. 10.1124\/mol.61.5.1255","journal-title":"Mol Pharmacol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033453640","article-title":"New insights into the molecular mechanisms of action of bisphosphonates","volume":"9","author":"Rogers MJ","year":"2003","unstructured":"Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003, 9:2643-58. 10.2174\/1381612033453640","journal-title":"Curr Pharm Des"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.0224","article-title":"Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase\/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo","volume":"255","author":"van Beek E","year":"1999","unstructured":"van Beek E, Pieterman E, Cohen L, L\u00f6wik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase\/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999, 255:491-4. 10.1006\/bbrc.1999.0224","journal-title":"Biochem Biophys Res Commun"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.08.008","article-title":"Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability","volume":"49","author":"Bellido T","year":"2011","unstructured":"Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011, 49:50-5. 10.1016\/j.bone.2010.08.008","journal-title":"Bone"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28965","article-title":"Bisphosphonates in breast cancer","volume":"137","author":"Mathew A","year":"2015","unstructured":"Mathew A, Brufsky A. Bisphosphonates in breast cancer. Int J Cancer. 2015, 137:753-64. 10.1002\/ijc.28965","journal-title":"Int J Cancer"},{"key":"ref51","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier S","year":"2000","unstructured":"Boissier S, Ferreras M, Peyruchaud O, et al.. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000, 60:2949-54.","journal-title":"Cancer Res"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-016-1224-8","article-title":"The miR-21\/PTEN\/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines","volume":"389","author":"Fragni M","year":"2016","unstructured":"Fragni M, Bonini SA, Bettinsoli P, et al.. The miR-21\/PTEN\/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2016, 389:529-38. 10.1007\/s00210-016-1224-8","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70704-5","article-title":"Bisphosphonates and phossy-jaw: breathing new life into an old problem","volume":"7","author":"Ashcroft J","year":"2006","unstructured":"Ashcroft J. Bisphosphonates and phossy-jaw: breathing new life into an old problem. Lancet Oncol. 2006, 7:447-9. 10.1016\/S1470-2045(06)70704-5","journal-title":"Lancet Oncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3233\/BD-2010-0327","article-title":"Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?","volume":"33","author":"Lipton A","year":"2011","unstructured":"Lipton A, Costa L, Coleman RE. Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?. Breast Dis. 2011, 33:59-69. 10.3233\/BD-2010-0327","journal-title":"Breast Dis"},{"key":"ref55","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/47.8.1410","article-title":"Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides","volume":"47","author":"Okabe R","year":"2001","unstructured":"Okabe R, Nakatsuka K, Inaba M, et al.. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides. Clin Chem. 2001, 47:1410-4.","journal-title":"Clin Chem"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.22763","article-title":"Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: a systematic review","volume":"24","author":"Lorenzo-Pouso AI","year":"2019","unstructured":"Lorenzo-Pouso AI, P\u00e9rez-Say\u00e1ns M, Gonz\u00e1lez-Palanca S, Chamorro-Petronacci C, Bag\u00e1n J, Garc\u00eda-Garc\u00eda A. Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: a systematic review. Med Oral Patol Oral Cir Bucal. 2019, 24:e26-36. 10.4317\/medoral.22763","journal-title":"Med Oral Patol Oral Cir Bucal"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/178578-enhancing-the-oral-rehabilitation-and-quality-of-life-of-bisphosphonate-treated-patients-the-role-of-dental-implants","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:48Z","timestamp":1707508488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/178578-enhancing-the-oral-rehabilitation-and-quality-of-life-of-bisphosphonate-treated-patients-the-role-of-dental-implants"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":56,"URL":"https:\/\/doi.org\/10.7759\/cureus.46654","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,7]]}}}